Divendres, 3 de juny de 2022 | 08:00h | Auditori | l'Acadèmia Can Caralleu
03-06-2022 | Auditori
08:30 - 09:00 Accreditation and material delivery
09:00 - 11:00 First session: AML biology and precision diagnosis
Moderador/a: Jordi Esteve Reyner | |
Hospital Clínic de Barcelona |
Mutational landscape of AML
Ponent: Verena Gaidzik | |
University Hospital of Ulm, Germany |
Germline predisposition to myeloid neoplasms
Ponent: Marta Pratcorona | |
Hospital de la Santa Creu i Sant Pau |
Measurable residual disease: development of precision tools for treatment decision
Ponent: Peter Valk | |
Erasmus University Medical Center, Rotterdam |
Clinical case: challenging diagnosis
Ponent: Àlex Bataller | |
Hospital Clínic de Barcelona |
11:00 - 11:30 Coffee break
11:30 - 13:30 Second session: targeted therapy for chemotherapy eligible patients
Moderador/a: Ana Garrido Díaz | |
Hospital de la Santa Creu i Sant Pau |
Frontline therapy with targeted agents
Ponent: Marina Diaz Beya | |
Hospital Clínic de Barcelona |
Salvage therapy option in the targeted therapy era
Ponent: Mar Tormo | |
Hospital Clínico Universitario de Valencia |
Allogeneic hematopoietic cell transplantation in AML: To whom, hen and how?
Ponent: Mi Kwon | |
Hospital General Universitario Gregorio Marañón, Madrid |
Clinical case: R/R AML
Ponent: Olga Salamero García | |
Hospital Universitari Valle de Hebrón, Barcelona |
13:30 - 14:30 Lunch
14:30 - 16:30 Third session: therapy for chemotherapy ineligible patients
Moderador/a: Ana Garrido Díaz | |
Hospital de la Santa Creu i Sant Pau |
Moderador/a: Jordi Esteve Reyner | |
Hospital Clínic de Barcelona |
Clonal evolution in AML: from CHIP to clonal response and beyond
Ponent: Josep Nomdedéu | |
Hospital de la Santa Creu i Sant Pau, Barcelona |
Venetoclax+hypomethylating agents and beyond: time for triplets & more?
Ponent: Courtney DiNardo | |
University of Texas MD Anderson Cancer Center, Houston |
How to manage failure to venetoclax?
Ponent: Montserrat Arnan Sangerman | |
ICO Hospital Duran i Reynals, Barcelona |
Clinical case: therapy for chemotherapy-ineligible patients
Ponent: Susana Vives | |
ICO- H. Germans Trias i Pujol |
16:30 - 17:30 Homenatge de la Societat Catalana d’Hematologia i Hemoteràpia al Dr. Jordi Sans i Sabrafen
Presentació
Presentador/a: Albert Altés Hernández | |
Aspectes científics
Ponent: Joan Vives-Corrons | |
El Dr. Jordi Sans i l’Escola d’Hematologia “Farreras-Valentí”
Ponent: Evarist Feliu | |
Aspectes humans
Ponent: Soledad Woessner | |
Cloenda de la sessió
17:30 - 18:00 Assembla General Ordinària
Presentació de la memòria d'activitats i econòmica de la SCHH 2021-2022.
Presentador/a: Albert Altés Hernández | |
Presentador/a: Carlos Fernández de Larrea Rodríguez | |
Presentació del guanyador/a de la (número de la beca) beca Janssen.
Presentador/a: Laura Carola Magnano Mayer | |
Resultat de les eleccions de la Junta de la SCHH.
Presentador/a: Laura Magnano | |
18:00 - 18:10 Closure of the meeting